Beam Therapeutics (BEAM) Invested Capital (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Invested Capital data on file, last reported at $1.2 billion in Q1 2026.

• Invested Capital for Q1 2026 came in at $1.2 billion, up 3.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 3.08% YoY), and the FY2025 annual result was $1.2 billion, up 67.94% from the prior year.
• Invested Capital retreated to $1.2 billion in Q1 2026 per BEAM's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Invested Capital peaked at $1.2 billion in Q4 2025 and troughed at $735.8 million in Q3 2022.
• A 5-year average of $908.6 million and a median of $857.7 million in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2024: Invested Capital surged 73.08% in 2022, then slipped 25.22% in 2024.
• A 5-year view of Invested Capital shows it stood at $751.8 million in 2022, then soared by 31.97% to $992.1 million in 2023, then dropped by 25.22% to $741.9 million in 2024, then surged by 67.94% to $1.2 billion in 2025, then dropped by 6.13% to $1.2 billion in 2026.
• Business Quant data shows BEAM's Invested Capital at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $972.5 million in Q3 2025.